| P2093 | author name string | John Kasckow | |
| | Sidney Zisook | |
| | Kandi Felmet | |
| P2860 | cites work | The Lifetime Risk of Suicide in Schizophrenia | Q22253035 |
| | Lithium for schizophrenia | Q24244034 |
| | Suicide as an outcome for mental disorders. A meta-analysis | Q28244203 |
| | Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome | Q28268543 |
| | Suicide among patients with schizophrenia: a consideration of risk and protective factors | Q28293391 |
| | Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation | Q28307938 |
| | Schizophrenia--a high-risk factor for suicide: clues to risk reduction | Q30312094 |
| | Schizophrenics kill themselves too: a review of risk factors for suicide | Q30451676 |
| | Suicide and schizophrenia: data from a prospective community treatment study | Q30583560 |
| | Treatment-resistant schizophrenia--the role of clozapine | Q32077288 |
| | Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? | Q33540378 |
| | Practice guideline for the treatment of patients with schizophrenia, second edition. | Q33976372 |
| | Suicidal risk during treatment with clozapine: a meta-analysis | Q33984401 |
| | 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). | Q34018491 |
| | The psychosocial treatment of schizophrenia: an update | Q34130736 |
| | Treatment of suicidality in schizophrenia. | Q34285238 |
| | Suicide and schizophrenia | Q34305454 |
| | Suicide behaviour over 18 months in recent onset schizophrenic patients: The effects of CBT | Q59784180 |
| | Suicide and Schizophrenia | Q60621774 |
| | Nursing schizophrenic patients who are at risk of suicide | Q60624165 |
| | The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia | Q61480079 |
| | The Iowa 500: suicide in mania , depression, and schizophrenia | Q66921036 |
| | Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study | Q68145833 |
| | Risk factors for suicide among patients with schizophrenia | Q68527816 |
| | Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial | Q68955932 |
| | Patterns of self-destructive behaviour in schizophrenia | Q69534526 |
| | Mortality in schizophrenia. A ten-year follow-up based on the Stockholm County inpatient register | Q69538086 |
| | Hospital suicides: are there preventable factors? Profile of the psychiatric hospital suicide | Q69718881 |
| | The special characteristics of suicide in hospital in-patients | Q70668585 |
| | Characterization of schizophrenic patients who commit suicide | Q71254279 |
| | Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study | Q71725113 |
| | Fluoxetine augmentation of clozapine treatment in patients with schizophrenia | Q71832229 |
| | A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia | Q71854843 |
| | Suicide in Chronic Schizophrenia | Q72534176 |
| | Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients | Q72574959 |
| | A clinical and epidemiological survey of parasuicide and suicide in Edinburgh schizophrenics | Q72602966 |
| | Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial | Q72666102 |
| | Case history and hospitalization factors in suicides of neuropsychiatric hospital patients | Q72831454 |
| | Suicide Risk in Placebo vs Active Treatment in Placebo-Controlled Trials for Schizophrenia | Q73270020 |
| | The relationship of akathisia with suicidality and depersonalization among patients with schizophrenia | Q74404689 |
| | Treatment of schizophrenia 1999. The expert consensus guideline series | Q77918229 |
| | Practice guideline for the assessment and treatment of patients with suicidal behaviors | Q79336422 |
| | Relapse prevention and recovery in the treatment of schizophrenia | Q79842985 |
| | Suicide in schizophrenia: the Iowa Record Linkage Study | Q93633646 |
| | Preventing suicide | Q94184319 |
| | Effect of psychopharmacotherapy on suicide risk in psychiatric inpatients | Q34334513 |
| | Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials | Q34456077 |
| | Two years of continued early treatment for recent-onset schizophrenia: a randomised controlled study | Q34571739 |
| | Treatment of Subsyndromal Depressive Symptoms in Middle-Age and Older Patients With Schizophrenia: Effect of Age on Response | Q34819160 |
| | Circumstances of suicide among individuals with schizophrenia | Q34985046 |
| | Co-occurring depressive symptoms in the older patient with schizophrenia | Q35008098 |
| | Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia | Q35102485 |
| | Suicide and schizophrenia: a review of literature for the decade (1990-1999) and implications for mental health nursing | Q35122924 |
| | Integrated treatment of schizophrenia | Q35576671 |
| | The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. | Q35593695 |
| | Antisuicide properties of psychotropic drugs: a critical review | Q35668658 |
| | The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update | Q35761336 |
| | Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. | Q36091773 |
| | Schizophrenia and suicide: systematic review of risk factors | Q36182528 |
| | Managing suicidality in schizophrenia | Q36933486 |
| | Prevention of suicide and attempted suicide in Denmark. Epidemiological studies of suicide and intervention studies in selected risk groups. | Q37061576 |
| | Atypical antipsychotics for people with both schizophrenia and depression. | Q37137044 |
| | Suicide within 12 months of contact with mental health services: national clinical survey | Q37449041 |
| | Management of schizophrenia with suicide risk | Q37640559 |
| | Psychodynamic treatment of schizophrenia: is there a future? | Q37933478 |
| | Depression, attempted suicide, and suicide in patients with chronic schizophrenia | Q38161346 |
| | Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial | Q38383845 |
| | 'Akinetic Depression' in Schizophrenia | Q39206918 |
| | Conditions predisposing to suicide: a review | Q39619249 |
| | Suicide among schizophrenics: a review | Q39813674 |
| | Postpsychotic depression in schizophrenia | Q40477964 |
| | Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia | Q40665719 |
| | Assessment and intervention for the suicidal patient with schizophrenia | Q41631277 |
| | Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia | Q42277407 |
| | Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial | Q43111012 |
| | Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study | Q43198845 |
| | Impact of clozapine on completed suicide | Q43625355 |
| | Suicide and other unexpected deaths among psychiatric in-patients. The Bristol confidential inquiry | Q43718889 |
| | Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database | Q43726217 |
| | A study of suicide in schizophrenic in-patients | Q43965320 |
| | Suicide in schizophrenics | Q43985470 |
| | Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. | Q44029969 |
| | Suicide risk in schizophrenia: an analysis of 17 consecutive suicides | Q44118620 |
| | Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study | Q44264704 |
| | Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). | Q44268852 |
| | Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial | Q44547218 |
| | Reducing the risk for suicide in schizophrenia and affective disorders | Q44662799 |
| | Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period | Q44754276 |
| | National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome | Q45287004 |
| | Gender Differences in Schizophrenia | Q46025594 |
| | Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. | Q46427053 |
| | The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences | Q47310602 |
| | Risk factors of suicide among schizophrenics. | Q47344164 |
| | OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis. One-year follow-up of a randomised controlled trial. | Q47345355 |
| | Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment | Q47351642 |
| | Depression, hopelessness and suicide in chronic schizophrenia | Q47356589 |
| | Suicidal behavior in schizophrenia: a test of the demoralization hypothesis | Q48292703 |
| | Factors predicting suicide in psychotic patients. | Q50544207 |
| | Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. | Q50633518 |
| | Suicide and schizophrenia: clozapine and the InterSePT study. International Clozaril/Leponex Suicide Prevention Trial. | Q50648512 |
| | The 15-year outcome of Chinese patients with schizophrenia in Hong Kong. | Q50862532 |
| | Risk factors for suicide in patients with schizophrenia: nested case-control study. | Q50923529 |
| | Mortality in current and former users of clozapine. | Q50928138 |
| | Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. | Q50936677 |
| | Life satisfaction and suicidal attempts among persons with schizophrenia | Q51015049 |
| | Relationships of age and axis I diagnoses in victims of completed suicide: a psychological autopsy study. | Q51026926 |
| | Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. | Q51068243 |
| | Cognitive behavioral therapy reduces suicidal ideation in schizophrenia: results from a randomized controlled trial. | Q51902335 |
| | Effectiveness of a brief cognitive-behavioural therapy intervention in the treatment of schizophrenia. | Q51956472 |
| | Mental disorder in elderly suicides: a case-control study. | Q51959370 |
| | Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. | Q51985891 |
| | Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. | Q51992021 |
| | Mental disorders in elderly suicide. | Q52019510 |
| | Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. A controlled retrospective study. | Q52023056 |
| | Assessment of suicide risk in psychiatric in-patients. | Q52091090 |
| | Suicide in psychiatric in-patients. | Q52097439 |
| | Suicide rates among public mental health patients. | Q52097833 |
| | TRANQUILIZERS AND SUICIDE IN THE SCHIZOPHRENIC PATIENT. | Q53041084 |
| | Depression in schizophrenia: recognition and management in the USA. | Q53327087 |
| | Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. | Q53360074 |
| | Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. | Q53589905 |
| | Critical treatment issues in suicide among schizophrenics. | Q53812243 |
| | Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with Schizophrenia in Quebec and Saskatchewan: A retrospective database study | Q57589554 |
| | Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity | Q59668672 |
| P433 | issue | 2 | |
| P921 | main subject | suicide | Q10737 |
| | schizophrenia | Q41112 |
| | suicide risk | Q47319077 |
| P304 | page(s) | 129-143 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | CNS Drugs | Q5013183 |
| P1476 | title | Managing suicide risk in patients with schizophrenia | |
| P478 | volume | 25 | |